Indian drugmaker Anthem Biosciences files for $397 mln IPO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 31 2024
0mins
Source: Reuters
Anthem Biosciences IPO Filing: Indian contract drugmaker Anthem Biosciences has filed for a ₹33.95 billion ($397 million) initial public offering, with investors like True North and DavosPharma selling shares, while the company itself will not sell any shares.
Growth of Indian IPO Market: The Indian IPO market has seen significant growth in 2021, raising $17.5 billion from over 300 companies, positioning it as a global leader in terms of proceeds and volumes, particularly as global drugmakers seek alternatives to Chinese contractors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
